Lymphoma, B-Cell: Clinical Trials

268 trials for Lymphoma, B-Cell, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

112 completed, 49 unknown, 39 recruiting, 28 active not recruiting. 268 Phase 3, 31 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 3268Completed 112, Unknown 49, Recruiting 39, Active not recruiting 28, Terminated 26, Not yet recruiting 7, Withdrawn 5, Enrolling by invitation 1, Suspended 1
Phase 231Recruiting 9, Completed 7, Unknown 6, Active not recruiting 3, Not yet recruiting 3, Terminated 3

Follow Lymphoma, B-Cell: new trials by email Literature Review of Lymphoma, B-Cell trials Research Report on Lymphoma, B-Cell

Trials (filtered) newest first · largest first

All 268 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Testing the Addition of a New Anti-Cancer Drug, Glofitamab to Usual Chemotherapy for Burkitt and Double Hit Lymphoma
Biospecimen Collection, Bone Marrow Biopsy, Carboplatin - Recurrent Burkitt Lymphoma, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements
Phase 2 / Phase 3RecruitingNational Cancer Institute (NCI)2712027-07-272026-11-17
A Study to Evaluate Surovatamig Combined With R-CHOP in Participants of 18 to < 80 Years of Age With Previously Untreated Large B-cell Lymphoma With IPI Score 2 to 5
Surovatamig, Rituximab, Cyclophosphamide - Large B-cell Lymphoma
Phase 3Not yet recruitingAstraZeneca12002026-12-222026-11-02
A Clinical Trial of MK-1045 With Zilovertamab Vedotin in Participants With Diffuse Large B-cell Lymphoma (MK-1045-010)
MK-1045, Zilovertamab vedotin, Rituximab - Lymphoma, Large B-Cell, Diffuse, Diffuse Large B-Cell Lymphoma
Phase 2 / Phase 3Not yet recruitingMerck Sharp & Dohme LLC4702026-12-132026-11-05
A Randomized, Open-Label, Multicenter Phase III Clinical Study of JS203 Plus Chemotherapy Versus Rituximab Plus Chemotherapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
JS203 in combination with gemcitabine and oxaliplatin, Rituximab in combination with gemcitabine and oxaliplatin - Diffuse Large B-Cell Lymphoma
Phase 3RecruitingShanghai Junshi Bioscience Co., Ltd.2822026-10-082026-10-14
Orelabrutinib Plus ICP 248 vs Orelabrutinib for Relapsed/Refractory Marginal Zone Lymphoma
Orelabrutinib, ICP-248 - Relapsed/Refractory Marginal Zone Lymphoma (MZL)
Phase 3Not yet recruitingBeijing InnoCare Pharma Tech Co., Ltd.2922026-10-012026-10-27
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
IgPro20 - Secondary Immune Deficiency
Phase 3RecruitingCSL Behring632026-09-152026-10-14
International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020)
Inotuzumab ozogamicin (INO), Blinatumomab - B-Cell Acute Lymphoblastic Leukaemia
Phase 3RecruitingCharite University, Berlin, Germany7502026-09-012026-10-26
Birelentinib Plus R-CHOP in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma (TAI-SHAN19)
Birelentinib, Rituximab, Cyclophosphamid - Diffuse Large B-Cell Lymphoma (DLBCL)
Phase 2 / Phase 3Not yet recruitingDizal Pharmaceuticals8802026-09-012026-08-05
Immunoglobulin Replacement Therapy (IgRT) Versus Antibiotic Prophylaxis (PA) in Patients Treated by CD19-targeted Chimeric Antigen Receptor (CAR)T Cells for a B Cell Acute Lymphoblastic Leukemia or a B Cell Lymphoma
Immunoglobulin, antibiotic prophylaxis - Chimeric Antigen Receptor T-cell Therapy, B Cell Acute Lymphoblastic Leukemia (B-ALL)
Phase 3Not yet recruitingAssistance Publique - Hôpitaux de Paris2282026-09-012026-08-10
Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL
NX-5948, Pirtobrutinib - B-cell Lymphoma, Chronic Lymphocytic Leukemia
Phase 3RecruitingNurix Therapeutics, Inc.6202026-08-032026-08-31
Chidamide for Maintenance Treatment of HBV-infected Diffuse DLBCL in Patients Initially Treated With R-CHOP
Chidamide, Entecavir Tablets - Diffuse Large B-Cell Lymphoma (DLBCL)
Phase 3RecruitingOu Bai, MD/PHD2002026-05-302026-03-25
A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)
MK-1045, Blinatumomab, Acetaminophen - B-cell Acute Lymphoblastic Leukemia
Phase 2 / Phase 3RecruitingMerck Sharp & Dohme LLC3402026-05-182026-11-10
A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCL
HMPL-760, HMPL-760 Placebo, R-GemOx - Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Phase 3RecruitingHutchmed2402026-03-202026-11-10
Modified DHAP Versus Standard DHAP in Relapsed/Refractory Diffused Large B-cell Lymphoma.
Cisplatin (modified schedule), Cisplatin, Dexametasone - DLBCL - Diffuse Large B Cell Lymphoma
Phase 3RecruitingKing Edward Medical University742026-03-182026-08-10
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
rondecabtagene autoleucel, axicabtagene ciloleucel, lisocabtagene maraleucel - Large B-cell Lymphoma, Lymphoma, B-Cell
Phase 3RecruitingLyell Immunopharma, Inc.4002026-01-122026-11-04
A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia
Fludarabine, Cyclophosphamide, CAR-T - B-cell Acute Lymphoblastic Leukemia
Phase 3RecruitingMemorial Sloan Kettering Cancer Center1302025-10-202026-11-12
NexCAR19 (Talikabtagene Autoleucel) in Relapsed/Refractory B-Cell Malignancies (NexCAR19)
Talikabtagene Autoleucel - Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia (B-ALL), Relapsed/Refractory Non-Hodgkin Lymphoma
Phase 2 / Phase 3RecruitingHealth Institutes of Turkey402025-09-112026-03-30
Xinlikang Capsule for Chemotherapy-induced Fatigue and Immune Disorders in Diffuse Large B Lymphoma
Xinlikang capsules, mimic capsules - Diffuse Large B-Cell Lymphoma (DLBCL)
Phase 2 / Phase 3RecruitingSun Yat-sen University802025-09-112025-11-26
A Phase III Clinical Study of Purinostat Mesylate for Injection in Patients With Diffuse Large B-cell Lymphoma
Purinostat Mesylate for Injection, Selinexor Tablets - Recurrent and Refractory Diffuse Large B-cell Lymphoma
Phase 3RecruitingChengdu Zenitar Biomedical Technology Co., Ltd3902025-07-182025-09-19
A Study of Reduced Dose Radiation Therapy for People With B-Cell Lymphomas
Radiation (Standard), Radiation (Very low dose) - Follicular Lymphoma, Marginal Zone Lymphoma
Phase 3RecruitingMemorial Sloan Kettering Cancer Center3752025-06-092026-10-26

Showing 20 of 268. Sign in to see all of them.

Narrower conditions

Lymphoma, Large B-Cell, Diffuse (185)  ·  Lymphoma (87)  ·  Lymphoma, Non-Hodgkin (80)  ·  Lymphoma, Follicular (77)  ·  Burkitt Lymphoma (76)  ·  Lymphoma, B-Cell, Marginal Zone (71)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (58)  ·  Lymphoma, Mantle-Cell (54)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (51)  ·  Lymphoma, Large-Cell, Immunoblastic (50)  ·  Hodgkin Disease (35)  ·  Multiple Myeloma (29)  ·  Leukemia (28)  ·  Leukemia, Myeloid, Chronic-Phase (27)

Broader conditions

Hemic and Lymphatic Diseases (268)  ·  Neoplasms by Histologic Type (267)  ·  Immune System Diseases (266)  ·  Immunoproliferative Disorders (265)  ·  Lymphatic Diseases (265)  ·  Lymphoproliferative Disorders (259)  ·  Neoplasms (253)  ·  Lymphoma, Non-Hodgkin (188)  ·  Lymphoma (181)  ·  Hematologic Diseases (81)  ·  DNA Virus Infections (76)  ·  Epstein-Barr Virus Infections (76)  ·  Herpesviridae Infections (76)  ·  Leukemia, Lymphoid (76)

Interventions

Rituximab (115)  ·  Cyclophosphamide (75)  ·  Vincristine (65)  ·  Doxorubicin (62)  ·  Prednisone (56)  ·  Etoposide (33)  ·  Cytarabine (28)  ·  Radiotherapy (25)  ·  Methotrexate (22)  ·  Dexamethasone (20)  ·  Lenalidomide (19)  ·  Gemcitabine (18)  ·  Filgrastim (16)  ·  Bendamustine Hydrochloride (14)  ·  Prednisolone (13)

Sponsors

Children's Oncology Group (9)  ·  National Cancer Institute (NCI) (9)  ·  Hoffmann-La Roche (8)  ·  Lymphoma Study Association (8)  ·  Ruijin Hospital (8)  ·  Memorial Sloan Kettering Cancer Center (6)  ·  European Organisation for Research and Treatment of Cancer - EORTC (5)  ·  Fred Hutchinson Cancer Center (5)  ·  Incyte Corporation (5)  ·  Loxo Oncology, Inc. (5)  ·  Fondazione Italiana Linfomi - ETS (4)  ·  Genmab (4)  ·  German High-Grade Non-Hodgkin's Lymphoma Study Group (4)  ·  Gilead Sciences (4)  ·  Merck Sharp & Dohme LLC (4)

Countries

United States (126)  ·  China (85)  ·  France (70)  ·  United Kingdom (65)  ·  Italy (64)  ·  Australia (59)  ·  Canada (59)  ·  Spain (55)  ·  Belgium (54)  ·  Germany (53)  ·  Poland (47)  ·  Israel (42)  ·  South Korea (41)  ·  Czechia (40)  ·  Switzerland (37)

Top investigators

Corinne Haioun, MD (3)  ·  Brenda Sandmaier (2)  ·  Catherine Patte, MD (2)  ·  David J. Straus, MD (2)

Results publications

PMID 26373676, PMID 27282998, PMID 42699559, PMID 11807147, PMID 16754935, PMID 23065509, PMID 23233721, PMID 30770362, PMID 32499241, PMID 32589970, PMID 32817282, PMID 33288485, PMID 34515338, PMID 37890117, PMID 39121442, PMID 39563886, PMID 41671463, PMID 41749915, PMID 42329537, PMID 10820362, PMID 12419745, PMID 14998846, PMID 15459300, PMID 15621843, PMID 15659500, PMID 15867204, PMID 15914552, PMID 16148284, PMID 16449523, PMID 16648042, PMID 16710026, PMID 16879771, PMID 16888080, PMID 17071492, PMID 17132719, PMID 17138821, PMID 17397698, PMID 17400912, PMID 17439836, PMID 17654614, PMID 17785567, PMID 17889355, PMID 17971487, PMID 18005385, PMID 18065407, PMID 18226581, PMID 18256325, PMID 18293016, PMID 18371107, PMID 18400558

NIH funding

2023 (9), U10CA180886 (5), U10CA098543 (4), 2016 (3), 2017 (3), 2025 (3), U10CA032102 (3), U10CA180821 (3), 2019 (2), P01CA015396 (2), P30CA006973 (2), P30CA015083 (2), P30CA015704 (2), P30CA068485 (2), U10CA021115 (2)